SPONSORSHIP ALLIANCE NEWS
On January 26, 2023, Accuray Incorporated announced that the European Radiosurgery Center Munich has selected a second CyberKnife® System, the latest generation CyberKnife S7™ System, to enable their team to treat the high volume of patients they see in their practice who would benefit from the extremely precise radiation treatments it delivers. The Center was an early adopter of CyberKnife radiosurgery and continues to pioneer new ways to use the system in the non-invasive treatment of certain neurological conditions and tumors. ~The center believes the CyberKnife System is the #1 tool for delivery of advanced radiosurgery treatments.
University Hospitals (UH) Seidman Cancer Center in Cleveland has selected a MRIdian MR-Guided Radiation Therapy System as part of a master agreement for the purchase of up to four systems, and will be the first in Ohio at a research and teaching hospital to offer the precision of MRIdian's advanced MRI-guided radiation therapy to cancer patients throughout the region for pancreas, prostate, kidney, gynecological, lung, liver, breast, brain, spine, and oligometastatic cancers.
Chindex Medical Limited (Chindex), through its subsidiary, has ordered 10 MRIdian® MR-Guided Therapy Systems. This approval expands MRIdian's global reach and offers cancer patients a new radiation therapy option, MRIdian Stereotactic MRI-Guided Adaptive Radiotherapy (SMART).
Findings from the phase III randomized controlled MIRAGE trial (NCT04384770) were published on January 12 in JAMA Oncology. The MIRAGE trial compared MRI-guided and CT-guided stereotactic body radiation therapy (SBRT) for localized prostate cancer and found MRI-guided radiation therapy – delivered with MRIdian – to be superior in substantially reducing acute genitourinary (GU) and gastrointestinal (GI) toxicity. MRI-guided radiation was also associated with significantly better patient-reported quality of life metrics.
SCINTIX™ biology-guided radiotherapy is now cleared by the FDA to treat patients with lung and bone tumors. SCINTIX therapy is the first and only radiotherapy that allows each cancer’s unique biology to autonomously determine where and how much radiation to deliver, second-by-second, during actual treatment delivery. This expands the RefleXion® X1 into the only dual-treatment modality platform that can treat patients with indicated solid tumors of any stage.
On January 1, 2023, Junxin Oncology Group and BOAO Evergrande International Hospital formed a partnership for cancer care, and Junxin will provide daily management and operation of the radiation oncology department at BOAO. The hospital is located at Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province, China. This hospital had been affiliated to Brigham and Women’s Hospital (BWH) for five years from 2016 to 2021. With this addition, Junxin is providing cancer care for more than 2000 patients annually at its four cancer centers distributed throughout four provinces in China as a medical group founded just three years ago. All of Junxin’s resources, such as MDT, chart round, internal training, cloud-based management, medical experts, will be available for BOAO.
Assistant Professor of Radiation Oncology at Weill Cornell Medicine in New York City, Dr. Himanshu Nagar supervises the region’s only MRIdian MR-guided radiation therapy machine, created by ViewRay. MRIdian provides MRI-guided radiotherapy, which leads to a more precise prostate cancer treatment while significantly limiting or eliminating the side effects of treatment.
A paper authored by John Ng, MD, Ryan Pennell, MBA, and Sylvia Formenti, MD has been published to study the feasibility of delivering MRI-guided partial breast radiotherapy or Precision Prone Irradiation (PPI) to treat DCIS and early stage breast cancer patients. The study concludes that MRI-guided partial breast radiotherapy as a breast radiotherapy technology is feasible and is a potential high clinical impact application of MRgRT. PPI has the potential to improve the therapeutic index of breast radiotherapy by more accurately delivering radiation dose to the cavity target and decreasing toxicities associated with radiation to the surrounding normal tissues.
The target: a substantial 9.42 cc tumor. The treatment: world-class ZAP-X SRS with a remarkably low 5.9 Gy max dose to the optic chiasm. To understand how the vault-free, cobalt-free ZAP-X defines new standards in SRS dosimetry, request the study at info@zapsurgical.com
The first ZAP-X installation in France is complete! Congratulations to the Centre de Cancérologie de la Porte de Saint-Cloud (CCPSC) in Boulogne-Billancourt. First patient treatments expected to begin early 2023. Constrained by a small space in a crowded urban setting, see the vault-free ZAP-X find its new home in a retrofitted conventional radiation bunker. Watch the video at https://www.youtube.com/watch?v=hKY7DSKeMDo
University Hospital in Olsztyn to become the first in Poland to offer vault-free, cobalt-free ZAP-X Gyroscopic Radiosurgery - the latest advance in surgical robotics. First patient treatments expected to commence in early 2023.
As the sponsor of the meeting, Vision RT announces that abstracts are open for the US Annual SGRT Community Meeting, being held in the fabulous, retro-futuristic TWA hotel in New York's JFK airport on May 11 - 12, 2023. We invite you to submit on any surface guidance topic. Travel grants are available for successful submissions. The abstract window will close on Monday, February 6, 2023.
Attendance to this event will be completely FREE and 100% peer-driven, with all sessions and talks delivered by SGRT users. As in previous years, the two-day event will be made up of presentations, workshops, latest innovations and applications, real-life case reports, and fun networking with peers and vendors.
Founded in 2001, Vision RT invented SGRT and remains the market leader in this field. SGRT makes every step of radiotherapy safer, more effective, and more comfortable for patients. Today, we celebrate an important milestone: more than 2,000 systems in active clinical use, worldwide.
Vision RT’s technology is used by all 15 of the top “Best Hospitals for Cancer” in the US and in 39 of the top 50. We have partnered with clinics to transform SGRT from a niche technology to a core part of a new standard of care, with AAPM guidelines on its use and applications for more than 10 different cancer types.
Accuray Exchange (AEx), the peer community for Accuray users has been transformed. The site has a new look but that's not all, there is a new discussion forum to support members in their daily practice. Join today and start availing of the benefits. Connect. Exchange. Learn.
RefleXion's newly named SCINTIX biology-guided radiotherapy combines radiotherapy with PET-CT to treat cancer using PET emissions created by the tumor itself. SCINTIX technology leverages radiotracers to track both expected and unexpected tumor motion. Click the button below to learn more.
Researchers presented eight abstracts evaluating the potential use of SCINTIX™ biology-guided radiotherapy. Two abstracts were also showcased during ASTRO's Quick Pitch session on "PET and Novel Techniques for Treatment."
Elekta Esprit, the new Leksell Gamma Knife® radiosurgery platform, recently showcased at ASTRO, received U.S. FDA 510(k) clearance on 28th October 2022.
Esprit combines a variety of innovations in a single platform. Leksell Gamma Knife® Lightning allows for high quality plan creation in <1 min further enabling same day radiosurgery. Esprit offers clinicians the option of frameless or frame-based workflows with the new Vantage™ system. Esprit targets the smallest and most challenging intracranial tumors and lesions with minimal effect on healthy tissue. This vital precision makes Esprit the gold standard in radiosurgery. Elekta Esprit - Protect the mind, protect the person.
The center reached the patient milestone in less than three years by leveraging MRIdian to treat a wide variety of patients including those with complex and hard to treat tumors, demonstrating the system's efficiency and clinical value.
ViewRay announced that SUNY Upstate Cancer Center in Syracuse, New York has selected MRIdian MRI-Guided Radiation Therapy System and will be the first in Upstate New York to offer the precision of MRIdian's advanced MRI-guided radiation therapy to cancer patients throughout the region for pancreas, prostate, lung, liver, breast, and oligometastatic cancers.
LAP-ABLATE, a prospective multi-center international randomized controlled trial will compare 2-year overall survival in pancreatic cancer patients receiving post-chemotherapy ablative MRIdian SMART vs. chemotherapy alone.
The primary objective of the SMART Pancreas study of low grade 3+ toxicity was met; exploration of secondary outcomes underway to confirm local control rates and patient outcomes with MRIdian SMART.
Final outcomes comparing acute grade ≥2 genitourinary toxicity following MRI- vs. CT-guided prostate SBRT presented at ASTRO 2022.
Medical University of Olsztyn in Poland to soon offer the latest advance in dedicated cranial radiosurgery.
Ever wonder what a vault-free ZAP-X might look like in a hospital lobby, a meeting space, or an empty room? Well now you can! Using a mobile phone or tablet, see the ZAP-X anywhere, anytime in 360-degrees. Just click below and follow the prompts (use a mobile phone or tablet).
Built In recognizes RefleXion as an organization delivering on the search for solutions to new and longstanding problems in healthcare. Gopi Kuduvalli, Ph.D., vice president of product engineering, talked with Built In about RefleXion's work to create a new cancer treatment modality through biological guidance.
DENVER, Sept. 7, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the company's MRIdian MRI-Guided Radiation Therapy System has received approval from the Chinese regulatory authority National Medical Products Administration (NMPA), allowing for its sale and utilization throughout China.
New agreement expands access to precision radiotherapy to more cancer patients in the UK.
First MRIdian system to be installed at MD Anderson main campus at the Texas Medical Center in Houston.
Ever wonder what a vault-free ZAP-X might look like in a hospital lobby, a meeting space, or an empty room? Well now you can! Using a mobile phone or tablet, see the ZAP-X anywhere, anytime in 360-degrees. Just click below and follow the prompts. (Reminder: use a mobile phone or tablet).
Site to be Among Europe’s First to Offer Groundbreaking Innovation in Non-Invasive Treatment for Brain Tumors.
Multi-year campaign will highlight clinical evidence and patient impact of MRIdian for cancer treatment.
This is the First Hospital in Texas and the Third VA Hospital to Offer MRIdian® MRI-guided Radiation Therapy Cancer Treatment.
Largest Cancer Center in Japan Enhances its Real-Time Soft-Tissue Tracking and On-Table Adaptive Delivery with MRIdian System.
Convenient access to advanced vault-free, cobalt-free SRS platform now available in the Rocky Mountain region via modern outpatient setting.
System implementation of the ZAP-X at Centre de Cancérologie de la Porte de Saint-Cloud (CCPSC) in Boulogne-Billancourt has officially begun. Constrained by a typical small space often found in dense urban settings, the vault-free ZAP-X looks to begin patient treatments by year end. Voilà!
We are excited to announce a three-system contract with Select Healthcare, a developer of affiliated cancer facilities throughout the United States. "The creation of these initial three new free-standing radiotherapy centers will [allow us, following clearance] to bring RefleXion’s novel BgRT to local communities so that patients with solid tumor cancers can receive state-of-the-art cancer care near their home," said Matthew Cutler, CEO, president and founder of Select Healthcare.